Quarterly report pursuant to Section 13 or 15(d)

Unaudited Condensed Consolidated Statements of Operations

v3.22.2
Unaudited Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Revenue:        
Product revenue, net $ 18,235 $ 15,288 $ 39,031 $ 26,007
Other revenue 56   2,556  
Total Revenue 18,291 15,288 41,587 26,007
Operating expenses        
Cost of goods sold-product revenue 7,633 7,484 15,836 11,392
Research and development 2,609 29 3,875 29
Research and development - licenses acquired   13,743   13,743
Selling, general and administrative 15,191 7,795 29,906 14,021
Total operating expenses 25,433 29,051 49,617 39,185
Loss from operations (7,142) (13,763) (8,030) (13,178)
Other expense        
Interest income (4)   (7)  
Interest expense 454 1,342 843 1,563
Change in fair value of derivative liability   182   182
Total other expense 450 1,524 836 1,745
Loss before income taxes (7,592) (15,287) (8,866) (14,923)
Income tax (benefit) expense (64) (3,422) 40 (3,326)
Net Loss $ (7,528) $ (11,865) $ (8,906) $ (11,597)
Net loss per common share-basic $ (0.43) $ (1.30) $ (0.51) $ (1.27)
Net loss per common share-diluted $ (0.43) $ (1.30) $ (0.51) $ (1.27)
Weighted average number of common shares-basic 17,455,894 9,161,333 17,386,538 9,159,841
Weighted average number of common shares-diluted 17,455,894 9,161,333 17,386,538 9,159,841